NASDAQ:PTLA - Portola Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$20.00 -0.20 (-0.99 %)
(As of 11/16/2018 04:00 PM ET)
Previous Close$20.20
Today's Range$19.25 - $20.52
52-Week Range$18.18 - $56.70
Volume993,882 shs
Average Volume1.76 million shs
Market Capitalization$1.33 billion
P/E Ratio-4.16
Dividend YieldN/A
Beta2.04
Portola Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics that could advance the fields of thrombosis and other hematologic diseases. The company's two FDA-approved medicines are Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo), an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of VTE in adult patients hospitalized for an acute medical illness. It is also advancing cerdulatinib, a Syk/JAK inhibitor for the treatment of hematologic cancers. In addition, the company is developing PRT2761, a Syk inhibitor candidate for the treatment for allergic conjunctivitis. Portola Pharmaceuticals, Inc. has collaboration agreements with Bristol-Myers Squibb; Pfizer Inc.; Bayer Pharma, AG; Janssen Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Dermavant Sciences GmbH; and Ora, Inc. The company was founded in 2003 and is headquartered in South San Francisco, California.

Receive PTLA News and Ratings via Email

Sign-up to receive the latest news and ratings for PTLA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PTLA
Previous Symbol
CUSIPN/A
Phone650-246-7000

Debt

Debt-to-Equity Ratio1.21
Current Ratio6.61
Quick Ratio6.51

Price-To-Earnings

Trailing P/E Ratio-4.16
Forward P/E Ratio-3.98
P/E GrowthN/A

Sales & Book Value

Annual Sales$22.55 million
Price / Sales58.92
Cash FlowN/A
Price / CashN/A
Book Value$2.51 per share
Price / Book7.97

Profitability

EPS (Most Recent Fiscal Year)($4.81)
Net Income$-286,090,000.00
Net Margins-1,020.52%
Return on Equity-135.08%
Return on Assets-69.69%

Miscellaneous

Employees252
Outstanding Shares66,430,000
Market Cap$1.33 billion
OptionableOptionable

Portola Pharmaceuticals (NASDAQ:PTLA) Frequently Asked Questions

What is Portola Pharmaceuticals' stock symbol?

Portola Pharmaceuticals trades on the NASDAQ under the ticker symbol "PTLA."

How were Portola Pharmaceuticals' earnings last quarter?

Portola Pharmaceuticals Inc (NASDAQ:PTLA) issued its quarterly earnings results on Wednesday, November, 7th. The biopharmaceutical company reported ($1.08) earnings per share for the quarter, beating analysts' consensus estimates of ($1.54) by $0.46. The biopharmaceutical company had revenue of $14.20 million for the quarter, compared to the consensus estimate of $7.10 million. Portola Pharmaceuticals had a negative return on equity of 135.08% and a negative net margin of 1,020.52%. Portola Pharmaceuticals's revenue for the quarter was up 270.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.41) earnings per share. View Portola Pharmaceuticals' Earnings History.

When is Portola Pharmaceuticals' next earnings date?

Portola Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 27th 2019. View Earnings Estimates for Portola Pharmaceuticals.

What price target have analysts set for PTLA?

8 brokerages have issued 1 year price objectives for Portola Pharmaceuticals' stock. Their forecasts range from $30.00 to $75.00. On average, they expect Portola Pharmaceuticals' share price to reach $46.1667 in the next twelve months. This suggests a possible upside of 131.2% from the stock's current price. View Analyst Price Targets for Portola Pharmaceuticals.

What is the consensus analysts' recommendation for Portola Pharmaceuticals?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Portola Pharmaceuticals in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Portola Pharmaceuticals.

What are Wall Street analysts saying about Portola Pharmaceuticals stock?

Here are some recent quotes from research analysts about Portola Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Portola Pharmaceuticals, Inc. is a biopharmaceutical company .It focuses on the development and commercialization of therapeutics for thrombosis, other hematologic disorders and inflammation. Portola Pharmaceuticals, Inc. is headquartered in South San Francisco, California. " (11/14/2018)
  • 2. Cowen Inc analysts commented, "Rhythm reported 2Q18 financial results yesterday and we spoke w/ mgmt for an update. As a reminder, the company completed enrollment of both setmelanotide Phase 3 trials in POMC and LepR Deficiency patients in Jun 2018. Mgmt reiterated guidance for results from these trials in 3Q19. We expect positive outcomes based on Phase 2 data. Encouraging long-term Phase 2 data in Bardet-Biedl (BBS) and initial Phase 2 data in Alstrom, POMC Heterozygous, and POMC Epigenetic were announced earlier this year and mgmt reiterated plans to start a single Phase 3 trial w/ both Bardet-Biedl and Alstrom patients in 2H18. Demonstration of consistent impact on appetite and weight across several genetic obesity diseases in 2Q18 has increased our conviction. BUY." (8/9/2018)

Has Portola Pharmaceuticals been receiving favorable news coverage?

News articles about PTLA stock have been trending neutral recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Portola Pharmaceuticals earned a news impact score of 0.3 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the immediate future.

Who are some of Portola Pharmaceuticals' key competitors?

Who are Portola Pharmaceuticals' key executives?

Portola Pharmaceuticals' management team includes the folowing people:
  • Ms. Mardi C. Dier, Exec. VP & CFO (Age 54)
  • Dr. John T. Curnutte, Exec. VP of R&D (Age 66)
  • Dr. John H. Lawrence III, Sr. VP & Chief Medical Officer (Age 60)
  • Mr. Tao Fu, Consultant (Age 46)
  • Mr. J. Scott Garland, Pres & CEO (Age 49)

Who are Portola Pharmaceuticals' major shareholders?

Portola Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.03%), Partner Fund Management L.P. (6.93%), William Blair Investment Management LLC (2.74%), FMR LLC (2.46%), Highland Capital Management LP (1.77%) and Jackson Square Partners LLC (1.53%). Company insiders that own Portola Pharmaceuticals stock include (Mauritius) Pte Ltd Maxwell, Charles J Homcy, Henry Ward Wolff, Jeffrey W Bird, John T Curnutte, Mardi Dier, Tao Fu and William Lis. View Institutional Ownership Trends for Portola Pharmaceuticals.

Which institutional investors are selling Portola Pharmaceuticals stock?

PTLA stock was sold by a variety of institutional investors in the last quarter, including Partner Fund Management L.P., FMR LLC, Wells Fargo & Company MN, Pictet Asset Management Ltd., Kornitzer Capital Management Inc. KS, Man Group plc, Allianz Asset Management GmbH and Ipswich Investment Management Co. Inc.. Company insiders that have sold Portola Pharmaceuticals company stock in the last year include Henry Ward Wolff, Tao Fu and William Lis. View Insider Buying and Selling for Portola Pharmaceuticals.

Which institutional investors are buying Portola Pharmaceuticals stock?

PTLA stock was acquired by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, Jackson Square Partners LLC, PointState Capital LP, Highland Capital Management LP, Macquarie Group Ltd., Asymmetry Capital Management L.P., Russell Investments Group Ltd. and Tocqueville Asset Management L.P.. View Insider Buying and Selling for Portola Pharmaceuticals.

How do I buy shares of Portola Pharmaceuticals?

Shares of PTLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Portola Pharmaceuticals' stock price today?

One share of PTLA stock can currently be purchased for approximately $19.97.

How big of a company is Portola Pharmaceuticals?

Portola Pharmaceuticals has a market capitalization of $1.33 billion and generates $22.55 million in revenue each year. The biopharmaceutical company earns $-286,090,000.00 in net income (profit) each year or ($4.81) on an earnings per share basis. Portola Pharmaceuticals employs 252 workers across the globe.

What is Portola Pharmaceuticals' official website?

The official website for Portola Pharmaceuticals is http://www.portola.com.

How can I contact Portola Pharmaceuticals?

Portola Pharmaceuticals' mailing address is 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-246-7000 or via email at [email protected]


MarketBeat Community Rating for Portola Pharmaceuticals (NASDAQ PTLA)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  394 (Vote Outperform)
Underperform Votes:  246 (Vote Underperform)
Total Votes:  640
MarketBeat's community ratings are surveys of what our community members think about Portola Pharmaceuticals and other stocks. Vote "Outperform" if you believe PTLA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTLA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel